ClinicalTrials.gov
ClinicalTrials.gov Menu

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01036087
Recruitment Status : Active, not recruiting
First Posted : December 21, 2009
Last Update Posted : November 14, 2018
Sponsor:
Collaborators:
Celgene Corporation
Amgen
Information provided by (Responsible Party):
M.D. Anderson Cancer Center